Skip to main content

ORIGINAL RESEARCH article

Front. Oncol., 25 February 2020
Sec. Cancer Molecular Targets and Therapeutics
Volume 10 - 2020 | https://doi.org/10.3389/fonc.2020.00075

RETRACTED: Inhibitor 9 Combined With Androgen Deprivation Therapy or Chemotherapy Delays the Malignant Behavior of Castration-Resistant Prostate Cancer Through K-Ras/PLCε/PKCε Signaling Pathway

Retracted

A retraction of this article was approved in:

  1. Retraction: Inhibitor 9 Combined With Androgen Deprivation Therapy or Chemotherapy Delays the Malignant Behavior of Castration-Resistant Prostate Cancer Through K-Ras/PLCϵ/PKCϵ Signaling Pathway

    1. Read retraction
\nJiayu LiuJiayu Liu1Yongbo ZhengYongbo Zheng1Yingying Gao,Yingying Gao2,3Zhen QuanZhen Quan1Bo QiaoBo Qiao4Luo Li,Luo Li2,5Ting LiTing Li2Limei DuanLimei Duan2Jinxiao YangJinxiao Yang2Chunli LuoChunli Luo2Xiaohou Wu Xiaohou Wu1*
  • 1Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
  • 2Department of Laboratory Diagnosis, Chongqing Medical University, Chongqing, China
  • 3Department of Laboratory Diagnosis, Clinical Medical College, Jiamusi University, Heilongjiang, China
  • 4Department of Orthopaedics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
  • 5Department of Laboratory Diagnosis, Chongqing Public Health Medical Treatment Center, Chongqing, China

This article has been retracted. Please follow the link to the full retraction notice for details.

Citation: Liu J, Zheng Y, Gao Y, Quan Z, Qiao B, Li L, Li T, Duan L, Yang J, Luo C and Wu X (2020) Inhibitor 9 Combined With Androgen Deprivation Therapy or Chemotherapy Delays the Malignant Behavior of Castration-Resistant Prostate Cancer Through K-Ras/PLCε/PKCε Signaling Pathway. Front. Oncol. 10:75. doi: 10.3389/fonc.2020.00075

Received: 08 November 2019; Accepted: 15 January 2020;
Published: 25 February 2020; Retracted: 27 May 2021.

Edited by:

Giuseppe Di Lorenzo, Federico II University Hospital, Italy

Reviewed by:

Gaetano Facchini, National Cancer Institute G. Pascale Foundation (IRCCS), Italy
Massimo Fantini, Precision Biologics, Inc., United States

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.